Research programme: sildenafil intranasal - BTG
Alternative Names: Sildenafil mesylateLatest Information Update: 21 Aug 2019
Price :
$50 *
At a glance
- Originator BTG
- Class Piperazines; Purines; Sulfones
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 03 Feb 2011 Discontinued - Preclinical for Erectile dysfunction in United Kingdom (Intranasal)
- 04 May 2007 Intranasal sildenafil is available for licensing worldwide (http:www.btgplc.com)